Polycythemia after vandetanib treatment in metastatic medullary thyroid carcinoma: A rare case report
Medullary thyroid cancer is a neuroendocrine tumor of the thyroid gland and its frequency is 1–2% among all thyroid cancers. Their prognosis is poor with a 10-year survival rate of 40%. Vandetanib, an oral tyrosine kinase inhibitor, is an effective treatment option for unresectable locally advanced...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-12-01
|
| Series: | Current Problems in Cancer: Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666621920300119 |